| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 26 | 2024 | 244 | 4.690 |
Why?
|
| Lung Neoplasms | 28 | 2024 | 553 | 4.190 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 11 | 2021 | 241 | 1.570 |
Why?
|
| Antineoplastic Agents | 6 | 2022 | 190 | 1.140 |
Why?
|
| Carcinoma, Squamous Cell | 10 | 2023 | 177 | 1.060 |
Why?
|
| Chemoradiotherapy | 11 | 2023 | 61 | 0.910 |
Why?
|
| Quinazolines | 3 | 2012 | 16 | 0.860 |
Why?
|
| Esophageal Neoplasms | 2 | 2019 | 54 | 0.720 |
Why?
|
| Aged | 38 | 2024 | 9256 | 0.710 |
Why?
|
| Neoplasm Staging | 18 | 2024 | 371 | 0.700 |
Why?
|
| Erlotinib Hydrochloride | 2 | 2018 | 11 | 0.670 |
Why?
|
| Esophagectomy | 1 | 2019 | 24 | 0.650 |
Why?
|
| Head and Neck Neoplasms | 4 | 2023 | 151 | 0.650 |
Why?
|
| Sarcopenia | 1 | 2019 | 31 | 0.630 |
Why?
|
| Kidney Glomerulus | 5 | 2019 | 48 | 0.630 |
Why?
|
| Female | 44 | 2024 | 15704 | 0.600 |
Why?
|
| Biomarkers | 5 | 2021 | 596 | 0.590 |
Why?
|
| Humans | 58 | 2024 | 28395 | 0.590 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2018 | 63 | 0.590 |
Why?
|
| Male | 42 | 2024 | 15269 | 0.580 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 68 | 0.570 |
Why?
|
| Prognosis | 15 | 2022 | 825 | 0.570 |
Why?
|
| Radiotherapy, Conformal | 2 | 2014 | 21 | 0.560 |
Why?
|
| Middle Aged | 35 | 2024 | 9250 | 0.560 |
Why?
|
| Amyloidosis | 5 | 2018 | 25 | 0.560 |
Why?
|
| Kidney | 6 | 2019 | 175 | 0.550 |
Why?
|
| ErbB Receptors | 6 | 2023 | 54 | 0.550 |
Why?
|
| Oropharyngeal Neoplasms | 4 | 2019 | 20 | 0.550 |
Why?
|
| Pneumonectomy | 2 | 2015 | 77 | 0.540 |
Why?
|
| Neoadjuvant Therapy | 4 | 2016 | 66 | 0.530 |
Why?
|
| Muscle, Skeletal | 1 | 2019 | 397 | 0.510 |
Why?
|
| Gene Dosage | 2 | 2012 | 18 | 0.490 |
Why?
|
| Retrospective Studies | 23 | 2023 | 3609 | 0.480 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2011 | 7 | 0.470 |
Why?
|
| Kidney Diseases | 5 | 2014 | 109 | 0.450 |
Why?
|
| Social Class | 1 | 2014 | 66 | 0.440 |
Why?
|
| Treatment Outcome | 23 | 2021 | 3615 | 0.430 |
Why?
|
| Postoperative Complications | 2 | 2019 | 931 | 0.420 |
Why?
|
| Glomerulonephritis | 3 | 2019 | 20 | 0.420 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2019 | 94 | 0.420 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2012 | 19 | 0.400 |
Why?
|
| Survival Analysis | 9 | 2021 | 267 | 0.390 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2011 | 42 | 0.380 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2022 | 206 | 0.370 |
Why?
|
| Immunotherapy | 2 | 2021 | 56 | 0.360 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2021 | 179 | 0.360 |
Why?
|
| Cyclooxygenase 2 | 2 | 2014 | 28 | 0.330 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2021 | 17 | 0.330 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 202 | 0.330 |
Why?
|
| Survival Rate | 8 | 2018 | 356 | 0.310 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2008 | 20 | 0.300 |
Why?
|
| Glomerulonephritis, Membranous | 2 | 2021 | 6 | 0.300 |
Why?
|
| Kidney Transplantation | 5 | 2019 | 133 | 0.280 |
Why?
|
| Adenocarcinoma | 3 | 2018 | 147 | 0.280 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 2 | 2018 | 5 | 0.280 |
Why?
|
| Adult | 17 | 2021 | 8097 | 0.270 |
Why?
|
| Mutation | 4 | 2023 | 353 | 0.260 |
Why?
|
| Proteomics | 3 | 2018 | 93 | 0.260 |
Why?
|
| Induction Chemotherapy | 2 | 2016 | 13 | 0.240 |
Why?
|
| Combined Modality Therapy | 7 | 2019 | 307 | 0.240 |
Why?
|
| Biopsy | 8 | 2019 | 220 | 0.240 |
Why?
|
| Follow-Up Studies | 8 | 2018 | 1858 | 0.240 |
Why?
|
| Databases, Factual | 6 | 2019 | 358 | 0.240 |
Why?
|
| Nephritis, Interstitial | 2 | 2014 | 7 | 0.230 |
Why?
|
| United States | 6 | 2019 | 2196 | 0.230 |
Why?
|
| Immunohistochemistry | 4 | 2021 | 362 | 0.230 |
Why?
|
| Body Composition | 1 | 2024 | 69 | 0.230 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2014 | 38 | 0.220 |
Why?
|
| Disease-Free Survival | 6 | 2018 | 177 | 0.220 |
Why?
|
| Aged, 80 and over | 11 | 2019 | 4851 | 0.220 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2023 | 50 | 0.220 |
Why?
|
| Laryngeal Neoplasms | 1 | 2023 | 32 | 0.210 |
Why?
|
| Molecular Targeted Therapy | 2 | 2015 | 35 | 0.210 |
Why?
|
| Primary Dysautonomias | 1 | 2023 | 4 | 0.210 |
Why?
|
| Mouth Neoplasms | 1 | 2023 | 21 | 0.210 |
Why?
|
| Cohort Studies | 7 | 2021 | 1926 | 0.210 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2021 | 17 | 0.200 |
Why?
|
| Maytansine | 1 | 2022 | 2 | 0.200 |
Why?
|
| Immunosuppressive Agents | 3 | 2019 | 140 | 0.200 |
Why?
|
| Immunoconjugates | 1 | 2022 | 7 | 0.200 |
Why?
|
| Nose Neoplasms | 1 | 2022 | 40 | 0.200 |
Why?
|
| Thoracic Neoplasms | 1 | 2022 | 9 | 0.200 |
Why?
|
| Immunoglobulin Light Chains | 2 | 2011 | 6 | 0.190 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2022 | 63 | 0.190 |
Why?
|
| Body Weight | 2 | 2024 | 144 | 0.190 |
Why?
|
| Weight Gain | 2 | 2012 | 66 | 0.190 |
Why?
|
| N-Acetylglucosaminyltransferases | 1 | 2021 | 3 | 0.180 |
Why?
|
| Carcinoma, Large Cell | 2 | 2018 | 12 | 0.180 |
Why?
|
| Lupus Nephritis | 1 | 2021 | 32 | 0.180 |
Why?
|
| Chemoradiotherapy, Adjuvant | 3 | 2015 | 17 | 0.170 |
Why?
|
| B7-H1 Antigen | 2 | 2021 | 9 | 0.170 |
Why?
|
| Creatinine | 3 | 2015 | 53 | 0.170 |
Why?
|
| Autoantibodies | 1 | 2021 | 80 | 0.170 |
Why?
|
| Allografts | 2 | 2019 | 218 | 0.170 |
Why?
|
| Age Factors | 4 | 2018 | 781 | 0.170 |
Why?
|
| Quality of Life | 3 | 2023 | 658 | 0.170 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 1 | 2019 | 1 | 0.160 |
Why?
|
| Human papillomavirus 16 | 1 | 2019 | 6 | 0.160 |
Why?
|
| Papillomavirus Infections | 2 | 2016 | 19 | 0.160 |
Why?
|
| Neoplasms | 1 | 2022 | 239 | 0.160 |
Why?
|
| Antibodies, Monoclonal | 2 | 2018 | 199 | 0.160 |
Why?
|
| Taxoids | 2 | 2015 | 10 | 0.160 |
Why?
|
| Nephrotic Syndrome | 1 | 2019 | 26 | 0.160 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2019 | 61 | 0.160 |
Why?
|
| Congo Red | 1 | 2018 | 1 | 0.150 |
Why?
|
| Tongue Neoplasms | 1 | 2018 | 19 | 0.150 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2018 | 9 | 0.150 |
Why?
|
| Registries | 2 | 2022 | 188 | 0.150 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 409 | 0.150 |
Why?
|
| Immunoglobulin G | 1 | 2018 | 94 | 0.140 |
Why?
|
| Proton Pump Inhibitors | 2 | 2014 | 14 | 0.140 |
Why?
|
| Laser Capture Microdissection | 2 | 2019 | 3 | 0.140 |
Why?
|
| Palliative Care | 2 | 2015 | 109 | 0.140 |
Why?
|
| Leukocyte Count | 1 | 2017 | 66 | 0.140 |
Why?
|
| Lymphocytes | 1 | 2017 | 63 | 0.130 |
Why?
|
| Neutrophils | 1 | 2017 | 110 | 0.130 |
Why?
|
| Prevalence | 2 | 2014 | 467 | 0.130 |
Why?
|
| Immunoglobulins | 1 | 2015 | 20 | 0.120 |
Why?
|
| Multiple Myeloma | 2 | 2012 | 21 | 0.120 |
Why?
|
| Carcinoma | 2 | 2015 | 69 | 0.120 |
Why?
|
| Prostaglandins | 1 | 2014 | 3 | 0.120 |
Why?
|
| Robotic Surgical Procedures | 1 | 2015 | 34 | 0.120 |
Why?
|
| Predictive Value of Tests | 3 | 2015 | 492 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 2 | 2014 | 378 | 0.120 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 506 | 0.110 |
Why?
|
| Preoperative Care | 1 | 2015 | 125 | 0.110 |
Why?
|
| Actuarial Analysis | 1 | 2014 | 8 | 0.110 |
Why?
|
| Academies and Institutes | 1 | 2014 | 10 | 0.110 |
Why?
|
| Cancer Care Facilities | 1 | 2014 | 7 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2015 | 112 | 0.110 |
Why?
|
| Propensity Score | 1 | 2014 | 36 | 0.110 |
Why?
|
| Parotid Gland | 1 | 2014 | 18 | 0.110 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 90 | 0.110 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 55 | 0.110 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 111 | 0.110 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 110 | 0.100 |
Why?
|
| Logistic Models | 1 | 2014 | 395 | 0.100 |
Why?
|
| Sulfonamides | 2 | 2014 | 41 | 0.100 |
Why?
|
| Prospective Studies | 1 | 2018 | 1804 | 0.100 |
Why?
|
| Young Adult | 5 | 2018 | 2069 | 0.100 |
Why?
|
| Disease Progression | 4 | 2021 | 717 | 0.100 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2012 | 2 | 0.100 |
Why?
|
| Lymphoma | 1 | 2012 | 38 | 0.100 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2012 | 21 | 0.100 |
Why?
|
| Papillomaviridae | 3 | 2016 | 18 | 0.100 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2011 | 2 | 0.100 |
Why?
|
| Paraproteinemias | 1 | 2011 | 6 | 0.100 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2011 | 9 | 0.100 |
Why?
|
| Therapies, Investigational | 1 | 2011 | 5 | 0.100 |
Why?
|
| Proteins | 1 | 2012 | 67 | 0.100 |
Why?
|
| Patient Selection | 3 | 2021 | 206 | 0.100 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2019 | 58 | 0.100 |
Why?
|
| Myeloproliferative Disorders | 1 | 2011 | 3 | 0.090 |
Why?
|
| Vascular Diseases | 1 | 2011 | 44 | 0.090 |
Why?
|
| Time Factors | 4 | 2019 | 1490 | 0.090 |
Why?
|
| Risk Factors | 4 | 2019 | 2408 | 0.090 |
Why?
|
| Xanthine Dehydrogenase | 1 | 2010 | 6 | 0.090 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 11 | 0.090 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2010 | 14 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2010 | 34 | 0.080 |
Why?
|
| Signal Transduction | 1 | 2012 | 447 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 3 | 2015 | 53 | 0.080 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2009 | 13 | 0.080 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2009 | 21 | 0.080 |
Why?
|
| Radiotherapy | 1 | 2009 | 34 | 0.080 |
Why?
|
| Kidney Function Tests | 3 | 2014 | 22 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2010 | 165 | 0.080 |
Why?
|
| Peptic Ulcer | 1 | 2008 | 4 | 0.080 |
Why?
|
| Celecoxib | 1 | 2008 | 5 | 0.080 |
Why?
|
| In Situ Hybridization | 1 | 2008 | 49 | 0.070 |
Why?
|
| Length of Stay | 2 | 2023 | 328 | 0.070 |
Why?
|
| Risk Assessment | 3 | 2019 | 676 | 0.070 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 2 | 2019 | 10 | 0.070 |
Why?
|
| Pyrazoles | 1 | 2008 | 58 | 0.070 |
Why?
|
| Mass Spectrometry | 2 | 2019 | 38 | 0.070 |
Why?
|
| Blood Group Incompatibility | 1 | 2005 | 2 | 0.060 |
Why?
|
| Splenectomy | 1 | 2005 | 7 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 517 | 0.060 |
Why?
|
| ABO Blood-Group System | 1 | 2005 | 5 | 0.060 |
Why?
|
| Kidney Failure, Chronic | 2 | 2021 | 165 | 0.060 |
Why?
|
| Pemetrexed | 2 | 2015 | 4 | 0.060 |
Why?
|
| Graft Rejection | 1 | 2005 | 71 | 0.060 |
Why?
|
| Lymph Nodes | 2 | 2016 | 70 | 0.060 |
Why?
|
| Adolescent | 3 | 2018 | 2307 | 0.060 |
Why?
|
| Case-Control Studies | 3 | 2012 | 593 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2018 | 25 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 166 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2022 | 730 | 0.060 |
Why?
|
| Radiotherapy Dosage | 2 | 2015 | 117 | 0.060 |
Why?
|
| Recurrence | 2 | 2018 | 322 | 0.060 |
Why?
|
| Etoposide | 2 | 2015 | 26 | 0.060 |
Why?
|
| Carboplatin | 2 | 2015 | 24 | 0.060 |
Why?
|
| Microscopy, Electron | 2 | 2015 | 67 | 0.050 |
Why?
|
| Paclitaxel | 2 | 2015 | 44 | 0.050 |
Why?
|
| Laryngectomy | 1 | 2023 | 21 | 0.050 |
Why?
|
| Acute Disease | 2 | 2014 | 208 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2023 | 35 | 0.050 |
Why?
|
| Aniline Compounds | 1 | 2023 | 36 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 34 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2015 | 269 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 16 | 0.050 |
Why?
|
| Minnesota | 2 | 2012 | 9 | 0.050 |
Why?
|
| Cetuximab | 1 | 2021 | 6 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2024 | 465 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2014 | 352 | 0.050 |
Why?
|
| Proteinuria | 2 | 2012 | 58 | 0.050 |
Why?
|
| C-Reactive Protein | 1 | 2022 | 104 | 0.050 |
Why?
|
| Phototherapy | 1 | 2021 | 36 | 0.050 |
Why?
|
| Antigens, Neoplasm | 1 | 2021 | 39 | 0.050 |
Why?
|
| Observer Variation | 1 | 2021 | 102 | 0.040 |
Why?
|
| Phenotype | 1 | 2021 | 310 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 9 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 44 | 0.040 |
Why?
|
| Reference Values | 1 | 2019 | 194 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 89 | 0.040 |
Why?
|
| Graft Survival | 1 | 2018 | 102 | 0.040 |
Why?
|
| Radiation Pneumonitis | 1 | 2015 | 3 | 0.030 |
Why?
|
| Hemoptysis | 1 | 2015 | 7 | 0.030 |
Why?
|
| Esophagitis | 1 | 2015 | 6 | 0.030 |
Why?
|
| Cough | 1 | 2015 | 9 | 0.030 |
Why?
|
| Markov Chains | 1 | 2015 | 32 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2015 | 22 | 0.030 |
Why?
|
| Chest Pain | 1 | 2015 | 19 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 52 | 0.030 |
Why?
|
| Complement C3 | 1 | 2015 | 6 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2015 | 3 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2015 | 7 | 0.030 |
Why?
|
| Radiation Injuries | 1 | 2015 | 32 | 0.030 |
Why?
|
| Dyspnea | 1 | 2015 | 42 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2015 | 36 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2015 | 8 | 0.030 |
Why?
|
| Diagnostic Errors | 1 | 2015 | 30 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 134 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2015 | 27 | 0.030 |
Why?
|
| Guanine | 1 | 2014 | 5 | 0.030 |
Why?
|
| Glutamates | 1 | 2014 | 9 | 0.030 |
Why?
|
| Pyrroles | 1 | 2014 | 24 | 0.030 |
Why?
|
| Steroids | 1 | 2014 | 25 | 0.030 |
Why?
|
| Glomerular Basement Membrane | 1 | 2014 | 3 | 0.030 |
Why?
|
| Mobility Limitation | 1 | 2015 | 94 | 0.030 |
Why?
|
| Antibodies | 1 | 2014 | 49 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2014 | 70 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2015 | 133 | 0.030 |
Why?
|
| Autoimmune Diseases | 1 | 2014 | 48 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2014 | 432 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2014 | 68 | 0.030 |
Why?
|
| Diet | 1 | 2015 | 220 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2014 | 300 | 0.030 |
Why?
|
| Laser Therapy | 1 | 2012 | 12 | 0.030 |
Why?
|
| Sequence Analysis, Protein | 1 | 2012 | 5 | 0.020 |
Why?
|
| Heavy Chain Disease | 1 | 2011 | 2 | 0.020 |
Why?
|
| Electrophoresis | 1 | 2011 | 6 | 0.020 |
Why?
|
| Age Distribution | 1 | 2012 | 89 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2012 | 160 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2012 | 82 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 199 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2014 | 689 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2012 | 108 | 0.020 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2011 | 24 | 0.020 |
Why?
|
| Thrombocythemia, Essential | 1 | 2011 | 1 | 0.020 |
Why?
|
| Polycythemia Vera | 1 | 2011 | 2 | 0.020 |
Why?
|
| Primary Myelofibrosis | 1 | 2011 | 4 | 0.020 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2011 | 9 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2011 | 43 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2011 | 169 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2011 | 42 | 0.020 |
Why?
|
| Choice Behavior | 1 | 2011 | 46 | 0.020 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2011 | 35 | 0.020 |
Why?
|
| Echocardiography | 1 | 2011 | 114 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 137 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2015 | 608 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2010 | 20 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 331 | 0.020 |
Why?
|
| Remission Induction | 1 | 2010 | 90 | 0.020 |
Why?
|
| Death-Associated Protein Kinases | 1 | 2010 | 4 | 0.020 |
Why?
|
| DNA Modification Methylases | 1 | 2010 | 4 | 0.020 |
Why?
|
| Comorbidity | 1 | 2012 | 500 | 0.020 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2010 | 5 | 0.020 |
Why?
|
| DNA Repair Enzymes | 1 | 2010 | 7 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 32 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 34 | 0.020 |
Why?
|
| Cadherins | 1 | 2010 | 36 | 0.020 |
Why?
|
| CpG Islands | 1 | 2010 | 54 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2010 | 52 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 54 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 96 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2010 | 65 | 0.020 |
Why?
|
| Algorithms | 1 | 2012 | 377 | 0.020 |
Why?
|
| Child | 1 | 2014 | 1421 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 239 | 0.020 |
Why?
|
| Smoking | 1 | 2010 | 176 | 0.020 |
Why?
|
| Lung | 1 | 2010 | 170 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 985 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 2005 | 43 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2005 | 183 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2005 | 84 | 0.020 |
Why?
|
| Animals | 1 | 2010 | 3780 | 0.010 |
Why?
|